The letter by Pezaro et al. [1] emphasizes a preference for changing nomenclature in prostate cancer, particularly avoiding the terminology ‘castration-resistant prostate cancer’, given that it can be off-putting and objectionable to patients and providers. However, their letter does not frame the taxonomy of the disease accurately; nor does it address the patient benefit derived from appropriately describing the biology for scientific investigation, the regulatory framework for drug development, and how this taxonomy aligns patients, clinicians and researchers in their understanding of the patient’s relevant biology within the continuum of his specific prostate cancer history. As such, until new findings evolve these issues, we advocate retaining the current terminology.

中文翻译：

---

为前列腺癌的临床应用命名疾病状态：任何其他名称的玫瑰都可能闻起来不那么甜。

佩扎罗等人的信。[1]强调倾向于更改前列腺癌的命名法，特别是避免使用术语“抗cast割性前列腺癌”，因为它可能会引起患者和医护人员的反感和反对。但是，他们的来信并没有准确地描述疾病的分类。它也没有解决因适当描述科研科学研究的生物学，药物开发的监管框架以及这种分类法如何使患者，临床医生和研究人员在其特定前列腺癌的连续性范围内理解患者的相关生物学而产生的患者收益。历史。因此，在新发现解决这些问题之前，我们主张保留当前的术语。